[Clinical experiences with 5% Tolectin (tolmetin) gel in patients with degenerative joint and spine diseases and soft tissue rheumatism].
The effectiveness and tolerability of Tolectin Gel 5% was evaluated in an open, multicentric study. 205 patients suffering from osteoarthrosis, spondylarthrosis, soft tissue rheumatism and post-traumatic pain were treated under conditions similar to practice. The topical preparation was administrated alone or when needed associated with Tolectin 400 mg/Capsules. Evaluation of symptoms and signs revealed no statistical difference of effectiveness between the two dosage groups. The topical preparation can be considered as effective as demonstrated by evolution of the assessed parameters under treatment. This positive result is confirmed by the opinion of the doctors and patients about the clinical evolution. The general assessment of the therapeutical efficacy and of the tolerance was confirmed by both observers. Strikingly these datas refers the osteoarthrosis and spondylarthroses patients as to those suffering from soft tissue rheumatism and posttraumatic pain. A dosis reduction of the oral other parenteral preparations is frequently possible by means of a concomitant topical treatment. In some types of soft tissue and articular rheumatism, chiefly in light cases, the local application alone can be sufficient. Tolectin Gel 5% constitutes a new possibility of therapy with local, efficient antirheumatic preparations.
D000287:Administration, Topical; D002214:Capsules; D004361:Drug Tolerance; D005260:Female; D005356:Fibromyalgia / Q000188:drug therapy; D005782:Gels; D006801:Humans; D007592:Joint Diseases / Q000188:drug therapy; D008297:Male; D010146:Pain / Q000188:drug therapy; D011758:Pyrroles / Q000627:therapeutic use*; D012216:Rheumatic Diseases / Q000188:drug therapy*; D013122:Spinal Diseases / Q000188:drug therapy; D014046:Tolmetin / Q000008:administration & dosage / Q000627:therapeutic use*
D002214:Capsules; D005782:Gels; D011758:Pyrroles; D014046:Tolmetin
Klinische Erfahrungen mit Tolectin (Tolmetin) Gel 5% bei Patienten mit degenerativen Gelenk- und Wirbelsäulenerkrankungen sowie Weichteilrheumatismus.